What General Fluidics does

General Fluidics Corporation is a privately held in vitro diagnostics company founded in 2014 and headquartered in Waltham, Massachusetts (Delaware-incorporated). The company develops the Axess™ point-of-care diagnostic platform, marketed as "The Point of Care Laboratory™." Axess is a compact benchtop system that integrates three gold-standard analytical technologies — hematology, clinical chemistry, and immunoassay — into a single device, paired with low-cost programmable cartridges that support standard, consolidated, and custom test panels. The platform is designed to deliver reference-laboratory-quality blood diagnostic results in minutes at the point of care rather than requiring sample transport to centralized labs with multi-day turnaround.

The business model is a classic razor-and-blade hardware-plus-consumable structure: Axess instruments are placed at clinics, urgent care centers, and rural healthcare settings, with recurring revenue from consumable cartridges across a broad test menu. Go-to-market is direct enterprise sales to healthcare providers. Commercial scaling and regulatory clearance are being supported through a June 2026 strategic partnership with Invetech, selected after a multi-continent search for its three decades of FDA/CE medical device manufacturing experience.

General Fluidics has raised approximately $34.6 million in cumulative venture funding across rounds in 2018 (~$5.4M), 2021 (~$6.65M), and mid-2024 ($22.6M Series B plus a separate SEC Form D exempt offering targeting ~$27.9M with ~$18.5M already sold). The leadership team — including President & CEO Robert Granier, CFO Robert Warren, VP of Assay Development Terry Walker, VP of Engineering Etienne Dano, and VP of Product Management & Quality David Dolinger — collectively brings over 100 years of IVD product development and commercialization experience. Co-founder Kenneth Kotz is also identified. The company is pre-revenue with no FDA/CE clearances yet disclosed.

Name

General Fluidics

Legal name

General Fluidics Corporation

Website

https://generalfluidics.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

General Fluidics develops the Axess™ point-of-care diagnostic platform, integrating hematology, clinical chemistry, and immunoassay on a single benchtop instrument with programmable cartridges to deliver reference-lab-quality blood results in minutes for clinics, urgent care centers, and rural healthcare settings.

Ownership category

akta.pro rank

Product category

Point-of-Care Diagnostics

NAICS

Analytical Laboratory Instrument Manufacturing (334516), In-Vitro Diagnostic Substance Manufacturing (325413), Surgical and Medical Instrument Manufacturing (339112)

SIC

Laboratory Analytical Instruments (3826), Surgical & Medical Instruments & Apparatus (3841), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics) (HLAHAAAN)

akta.pro secondary industries

Clinical Chemistry & Immunoassay Systems (HLAHAAAA), Hematology POCT (CBC/hemoglobin/hematocrit) (HLAHAOAD)

Keywords

• Point-of-care diagnostics
• Blood diagnostic testing
• In vitro diagnostics
• Clinical chemistry analyzers
• Hematology immunoassay systems

Headquarters

HQ city

Waltham

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Supply Chain, Marketing or Sales

Revenue model

1. Point-of-Care Diagnostic Platform Sales: Sale of Axess diagnostic instruments and consumable cartridges to healthcare facilities including clinics, urgent care centers, and rural settings. The platform uses low-cost programmable cartridges which likely represent recurring consumable revenue.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

General Fluidics develops the Axess point-of-care diagnostic platform, a compact benchtop system that integrates three gold-standard analytical technologies—hematology, clinical chemistry, and immunoassay—into a single instrument paired with low-cost programmable cartridges. The platform delivers reference-laboratory quality blood and urine diagnostic results in minutes at the point of care, targeting clinics, urgent care centers, and rural healthcare settings.

Product overview

General Fluidics offers a single unified product—the Axess™ point-of-care diagnostic platform, marketed as "The Point of Care Laboratory™." The platform integrates three gold-standard analytical technologies (hematology, clinical chemistry, and immunoassay) into a single compact benchtop system with low-cost programmable cartridges, enabling full test menus at the point of care rather than requiring samples to be sent to reference laboratories.

Differentiator

Problem solved

Functional benefit

Brands

• Axess: Point-of-care diagnostic testing platform integrating hematology, clinical chemistry and immunoassay technologies for blood diagnostics at the point of care

Quantifiable outcome

• Blood diagnostic results delivered in minutes rather than days
• +1 more outcomes

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• InvetechcoreStrategic or Co-development Partner · 4 June 2026Invetech serves as General Fluidics' development and scaleup partner for the Axess point-of-care diagnostic platform. After a global search spanning four continents, GF selected Invetech for its end-to-end manufacturing capability and three decades of experience developing FDA and CE-approved medical devices. The partnership aims to accelerate bringing high-quality diagnostic testing from central labs directly to clinics, urgent care centers, and rural settings, with results available within minutes at point of care.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• EKF Diagnostics: EKF offers POC chemistry, hemoglobin, and diabetes diagnostics for clinics and near-patient testing—a smaller but direct POC diagnostic peer in ambulatory settings.
• Randox Laboratories: Randox produces compact clinical chemistry analyzers (e.g., Evidence) and POC reagents aimed at decentralized testing—an adjacent competitor serving clinics and urgent care.
• Boule Diagnostics: Boule produces compact hematology analyzers (Swelab, Medonic) targeted at decentralized and small-lab settings—comparable customer segment and hematology focus.
• HemoCue: HemoCue specializes in POC hemoglobin and blood component testing, often used in primary care and rural settings—an adjacent POC diagnostics competitor with overlapping end users.

Direct peers

• Abbott Laboratories (i-STAT / Piccolo): Abbott's i-STAT and Piccolo systems are the dominant handheld/benchtop point-of-care blood diagnostic platforms, directly competing with Axess in clinical chemistry, immunoassay, and hematology at the point of care.
• Siemens Healthineers (epoc / RAPIDPoint): Siemens' epoc blood analysis system delivers POC clinical chemistry and immunoassay results, competing head-to-head with Axess for urgent care and clinic placements.
• Nova Biomedical: Nova manufactures Stat Profile and Nova Prime POC analyzers used for blood gas, chemistry, and critical care testing—directly comparable POC diagnostic modality and customer base.
• Sysmex: Sysmex is a global leader in hematology analyzers, including POC/compact hematology systems—competing directly with Axess's hematology capability in clinics and smaller labs.

Broad incumbents

• Roche Diagnostics: Roche operates cobas and other POC platforms spanning clinical chemistry and immunoassay, serving the same clinic and hospital customers as General Fluidics with broader menu and global reach.
• QuidelOrtho: QuidelOrtho offers Triage and Sofia POC immunoassay and rapid diagnostics, plus central lab products—an established competitor across the menu categories GF targets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/general-fluidics-corporation

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about General Fluidics